Lupin gets US FDA nod to market generic Tavaborole topical solution

The product will be manufactured at Lupin's facility in Pithampur, India.

Ad Marketing
Picture: Pixabay

Last Updated on February 10, 2021 by The Health Master

Global pharma major Lupin Limited has received approval for its tavaborole topical solution, 5%, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Kerydin topical solution, 5%, of Anacor Pharmaceuticals, Inc.

The product will be manufactured at Lupin’s facility in Pithampur, India.

Tavaborole topical solution, 5%, is an oxaborole antifungal indicated for the topical treatment of onychomycosis of the toenails due to trichophyton rubrum or trichophyton mentagrophytes.

Tavaborole topical solution had estimated annual sales of US$ 76 million in the US, according to IQVIA MAT December 2020.

Also read | Alembic Pharma gets 5 observations from USFDA

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates